Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal vs Intramuscular Influenza Vaccine in Elderly
NCT00383526Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2006
- Primary completion
- Jun 2009
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of IDflu in influenza (2 arms), sponsored by Sanofi. Primary endpoint: Seroprotection rate at 21 days. Started Sep 2006; status: completed.
02
Drugs
IDflu
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00383526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00383526.